The “DE-escalation of Breast Radiation” (DEBRA, NRG-BR007) study [56] is a multicenter Phase III study sponsored by NRG Oncology that is seeking to enroll 1670 women with T1N0 breast cancer with an ER+HER2- disease and an RS score ≤ 18. The gene discussed is ERBB2; the disease is breast carcinoma.